LISATA THERAP.INC.DL-001 Asset Resilience Ratio
LISATA THERAP.INC.DL-001 asset resilience ratio. LISATA THERAP.INC.DL-001 (8NE) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can LISATA THERAP.INC.DL-001 fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of LISATA THERAP.INC.DL-001 (2021–2025)
Asset resilience ratio of LISATA THERAP.INC.DL-001 from 2021 to 2025. This chart shows how LISATA THERAP.INC.DL-001's Asset Resilience Ratio has changed over time. Read total liabilities of LISATA THERAP.INC.DL-001 for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down LISATA THERAP.INC.DL-001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 8NE total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: LISATA THERAP.INC.DL-001 maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
LISATA THERAP.INC.DL-001 Industry Peers by Asset Resilience Ratio
Compare LISATA THERAP.INC.DL-001's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
LISATA THERAP.INC.DL-001 Asset Resilience Ratio by Year (2021–2025)
LISATA THERAP.INC.DL-001 asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for LISATA THERAP.INC.DL-001.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | €0.00 ≈ $0.00 |
€17.74 Million ≈ $20.74 Million |
-- |
| 2024-12-31 | 42.96% | €15.04 Million ≈ $17.58 Million |
€35.00 Million ≈ $40.92 Million |
-8.13pp |
| 2023-12-31 | 51.09% | €27.94 Million ≈ $32.67 Million |
€54.69 Million ≈ $63.94 Million |
+0.33pp |
| 2022-12-31 | 50.76% | €37.07 Million ≈ $43.34 Million |
€73.03 Million ≈ $85.38 Million |
-21.73pp |
| 2021-12-31 | 72.49% | €70.32 Million ≈ $82.21 Million |
€97.01 Million ≈ $113.41 Million |
-- |
About LISATA THERAP.INC.DL-001
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more